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Summary Clinical decision making which contraceptive regimen is optimal for an
individual woman with epilepsy is one of the most challenging tasks when taking care
of women with epilepsy. The bidirectional interactive potential of antiepileptic drugs
(AEDs) and hormonal contraceptives needs to be taken into account. Enzyme inducing
(EI)-AEDs may reduce the contraceptive efficacy of hormonal contraceptives. If
combined oral contraceptives (COCs) are used in combination with EI-AEDs, it is
recommended to choose a COC containing a high progestin dose, well above the dose
needed to inhibit ovulation, and to take the COC pill continuously (‘‘long cycle
therapy’’). But even with the continuous intake of a COC containing a higher progestin
dose contraceptive safety cannot be guaranteed, thus additional contraceptive
protection may be recommended. Progestin-only pills (POPs) are likely to be inef-
fective, if used in combination with EI-AEDs. Subdermal progestogen implants are not
recommended in patients on EI-AEDs, because of published high failure rates. Depot
medroxyprogesterone-acetate (MPA) injections appear to be effective, however they
may not be first choice due to serious side effects (delayed return to fertility, impaired
bone health). The use of intrauterine devices is an alternative method of contra-
ception in the majority of women, with the advantage of no relevant drug—drug
interactions. The levonorgestrel intrauterine system (IUS) appears to be effective,
even in women taking EI-AEDs. Likelihood of serious side effects is low in the IUS users.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
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enzyme inducing antiepileptic drugs (EI-AEDs) were
reported. Newer data show that it is not only the
decrease in contraceptive safety that needs to be
taken into account when taking care of women with
epilepsy on antiepileptic drugs (AEDs) and hormonal
contraceptives, but also the influence of the hor-
monal contraceptives on the efficacy of antiepilep-
tic drugs. Various mechanisms may explain these. Published by Elsevier Ltd. All rights reserved.
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metabolism by the hepatic Cytochrome P450 (CYP)
isoenzyme system or the Uridine-5-diphosphate-glu-
curonosyltransferase (UGT)-system. However, many
physicians and patients are unaware of this poten-
tial for interactions between enzyme-inducing AEDs
and hormonal contraception, which may result
in contraceptive failure or a decreased seizure
control.Effect of AEDs on hormonal
contraceptives
AEDs that may potentially impair contraceptive
safety of hormonal contraceptives via an increased
clearance of the synthetic steroids include the
‘‘strong CYP3A inducers’’ carbamazepine, pheny-
toin, phenobarbital and primidone as well as the
‘‘mild CYP3A inducers’’ oxcarbazepine, topiramate
and felbamate (Table 1). Although earlier data did
not show an effect of lamotrigine on contraceptive
safety, a recent pharmacokinetic study in healthy
women revealed a clinically relevant influence of
300 mg lamotrigine daily on a combined oral contra-
ceptive (COC) with 30 mg ethinylestradiol and
150 mg levonorgestrel: the area under the curve
(AUC) and the maximal plasma concentration (Cmax)
of the levonorgestrel decreased whereas the ethi-
nylestradiol pharmacokinetics were unchanged by
lamotrigine. FSH and LH (luteinizing hormone) con-
centrations increased (by 4.7-fold and 3.4-fold)
demonstrating a reduced suppression of the
hypothalamic—pituitarian axis.1 Although measure-
ment of serum progesterone showed no evidence of
ovulation, contraceptive safety cannot be guaran-
teed, especially if higher lamotrigine doses and
other COCs containing different progestins are used.
Combined oral contraceptives have two compo-
nents: an estrogen, usually ethinylestradiol, and a
progestin. The metabolism of ethinylestradiol













Topiramatemuch less is known about the metabolism of the
various progestins that are used in today’s COCs.
Therefore, results of a drug—drug interaction
study with a COC pill containing a specific progestin
cannot be transferred to other hormonal contra-
ceptives that contain a different progestin. This also
applies to the impact of AEDs in higher daily doses as
those used in published interaction studies.Effect of hormonal contraceptives on
AEDs
Most drug—drug interaction studies have focused on
the effect of AEDs on oral contraceptive safety.
Much less is known about the result of a coprescrip-
tion of hormonal contraceptives on AEDs, which is
surprising, since it is known for a long time that oral
contraceptives have a strong influence on drug
metabolizing enzymes. Lamotrigine was the first
AED that was evaluated in this respect: comedica-
tion with an ethinylestradiol containing hormonal
contraceptive results in clinically relevant decrease
of lamotrigine levels. In COCs, during the period ‘‘on
the pill’’ lamotrigine levels decrease by approxi-
mately 50%, followed by an increase of lamotrigine
levels in the contraceptive-free week up to 80—
100% of the baseline lamotrigine level. This is often
clinically relevant and may result in an increased
risk of seizure recurrence especially in week 2 and 3
on the pill or in concentration-dependent adverse
effects at the end of the pill-free interval.2—5 These
fluctuations are most likely due to an induction of
UGT1A4, the enzyme responsible for the glucoroni-
dation of lamotrigine, by ethinylestradiol.
Valproate levels also seem to be reduced by the
concomitant use of hormonal contraceptives.6,7
Just as with lamotrigine the magnitude of observed
fluctuations of the valproate levels appear to vary
interindividually.A dogma revisited: is the prescription
of COCs with 50 mg ethinylestradiol
adequate to improve contraceptive
safety?
Unwanted pregnancies due to contraceptive failure
of the chosen method should be avoided. In order to
improve contraceptive efficacy it is often recom-
mended that women on EI-AEDs should use COCs
with at least 50 mg ethinylestradiol. However, this
advice is problematic for two reasons: (1) there are
no published data to prove the efficacy of this
strategy, but reported pregnancies of women on
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diol; (2) the recommendation is not plausible, since
50 mg ethinylestradiol is still far below the dose that
is needed to inhibit ovulation (100 mg).
What can we do instead? Two alternatives most
likely to be superior to the old recommendation of













Nhe use of a COC containing a progestin dose well
above the dose needed to inhibit ovulation and the continuous use of the COC without a pill-free
interval (‘‘long cycle’’).
To understand why this strategy is probably very
effective one needs to know how modern oral con-
traceptives work. The main contraceptive mechan-
ism of COCs is ovulation inhibition. COCs suppress
the hypothalamic—pituitarian—ovarian axes result-
ing in an impaired follicular growth and anovulation.
Ovulation inhibition is accomplished by disturbing
the gonadotropin secretion at the hypothalamic and
pituitarian level with an inhibition of the preovula-
tory LH (luteinizing hormone) peak. Additionally,
synthetic progestins may directly influence ovarian
function by a direct inhibition of the ovarian steroid
biosyntheses. The reduced ovarian and follicular
activity is reflected in low estradiol and absent
progesterone serum concentrations. Modern COCs
have two components: ethinylestradiol and a pro-
gestin. Both are on their own able to inhibit ovula-
tion. However, in modern COCs ovulation inhibition
is mainly achieved by the progestin and not by
ethinylestradiol. The typical daily progestin dose
in today’s COCs is about 1.5—2 times the ovula-
tion-inhibiting dose (Table 2). Modern commonly
prescribed oral COCs contain only between 20 and
30 mg ethinylestradiol, which is far below the dose
that would be needed to inhibit ovulation (about
100 mg).9 In these COCs the estrogen is mainly












omegestrol acetate 5.0of the endometrium. It also reinforces the ovulation
inhibiting effect of the progestin, adding some extra
contraceptive safety. Thus, the use of a contracep-
tive containing 50 mg of ethinylestradiol does not
necessarily ensure contraceptive safety, if used in
combination with EI-AEDs that induce the metabo-
lism of the progestin as well. Nevertheless it may
improve cycle control.
To further improve contraceptive efficacy (addi-
tional to the use of a COC that contains a progestin
well above the dose needed to inhibit ovulation), it
is also recommended to use the COC without a pill-
free interval. If the COC is used the traditional way
(3 weeks on the COC, followed by 1 week off) FSH
and LH secretion recommence instantly after the
last day of pill intake, which explains the rapid
return to fertility after the discontinuation of a
COC. This immediate reactivation of the hypotha-
lamic—pituitarian—ovarian axes leads to the prompt
return of a follicular growth. During each 7-day pill-
free interval the development of new follicles starts
over again. This can be demonstrated by sequential
ultrasound measurements of the increasing follicu-
lar activity and the assessment of the rising estradiol
serum concentrations. With the 1st day back on the
pill, the follicular growth is disturbed. However it
always takes a couple of days of uninterrupted use of
the COC in adequate doses to ensure a definite
arrest of follicular development and anovulation.
This explains why missed pills in the 1st week of the
COC use (or progestin levels to too low to properly
inhibit this process, as it may happen due to a
comedication with EI-AEDs) may in particular pro-
mote ‘‘escape ovulations’’. If the COC is continu-
ously used without a pill-free interval gonadotropin
secretion and ovarian function is continuously sup-
pressed, which results in an enormous increase in
contraceptive efficacy.10 Additional to these effects
of the ‘‘long cycle’’ use of COCs, contraceptive
safety is further enhanced by other contraceptive
mechanisms, e.g. the uninterrupted thickening of
the cervical mucus (also referred to as ‘‘minipill
effect’’) or the continuous alteration of the endo-
metrium. Even if EI-AEDs happen to reduce the COC-
induced inhibition of ovarian function and even if
escape ovulation occurs, thesemechanisms still may
prevent pregnancy.
Although there is no doubt, that the contracep-
tive efficacy is improved by the continuous use of a
COC that contains a progestin in a high dose (well
above the dose that would be needed to inhibit
ovulation), full oral contraceptive safety cannot
be guaranteed in women with epilepsy taking strong
EI-AEDs. Thus additional contraceptive protection
(such as barrier methods as condoms) may be worth-
while.
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lamotrigine levels if used in
combination with ethinylestradiol
containing hormonal contraceptives?
Ethinylestradiol containing hormonal contracep-
tives (COCs, vaginal ring (Nuvaring1) or patch
(Evra1) may lead to clinically relevant lamotrigine
level fluctuations accompanied by a worsening of
seizure control. Simple lamotrigine dose adjust-
ment in order to improve seizure control may lead
to an overdosing and dose-dependent side effects in
the contraceptive-free interval. The easiest way to
stabilize lamotrigine levels and subsequently sei-
zure control and to avoid this overdosing is the
continuous use of the hormonal contraceptive with-
out a free interval. Since the ethinylestradiol-
induced decrease of lamotrigine levels may occur
very rapidly only a few days after the hormonal
contraceptive was started, it appears to be reason-
able to start lamotrigine dose adjustment shortly
after the initiation of the hormonal contraception.
In the majority of cases approximately a doubling of
the initial lamotrigine dose is needed to stabilize
lamotrigine levels.Are progestin-only methods suitable
for women with epilepsy on EI-AEDs?
In progestin-only methods the mechanism of contra-
ceptive action is dose-dependent. The low dose
progestin-only preparations, the progestin-only pills
(POPs), that are also referred to as minipills, contain
progestins below ovulation-inhibiting dose, e.g.
30 mg of levonorgestrel/day. Thus, ovulation is not
consistently inhibited. POPs exert their contracep-
tive effect mainly through the peripheral actions of
progestins: a thickening of the cervical mucus that
leads to impaired sperm penetration, an adverse
effect on the endometrium and a decrease in tubal
motility. Since the main mechanism of action is
peripheral, POPs need to be taken continuously
without a pill-free interval. Because of the very
low doses used, POPs are likely to be ineffective
in women on EI-AEDs.
The intermediate dose progestin-only methods
allow some follicular development, but inhibit ovu-
lation in almost all cycles. Typical examples are
Cerazette1 (a pill that contains 75 mg desogestrel
p.o./day), or the two progestin implants Implanon1
or Jadelle1. Implanon1 is a single rod contraceptive
implant that is inserted underneath the skin of the
upper arm. It contains 68 mg etonogestrel (active 3-
keto-metabolite of desogestrel) which is releasedover 3 years. Jadelle1 consists of two rods contain-
ing 75 mg levonorgestrel each, which is released
over a period of up to 5 years. Even though the
implants provide highly reliable contraception in
the general female population not on EI-AEDs, there
are published cases of contraceptive failures with
these methods.11—14 Thus, these intermediate dose
progestin-only methods are not recommended in
women with epilepsy on EI-AEDs.
The high dose injectable progestin-only formula-
tions inhibit ovulation. The two most widely used
preparations are depot medroxyprogestrone-
acetate (DMPA) and norethisterone enanthate
(NET-ET). These very high dose progestin-only depot
formulations are considered to provide effective
contraception in most publications, although clin-
ical trials to support this are lacking. Some authors
recommend shortening the interval between each
injection (e.g. from 12 to 10 weeks) in women on EI-
AEDs. Although it is plausible that these high dose
progestin-only depot preparations provide contra-
ceptive efficacy even if the patient is treated with
EI-AEDs they may not be first choice because of a
number of serious side effects: over the last couple
of years an increasing body of evidence was pub-
lished showing that particularly the long-term use of
DMPA may adversely affect bone mineral density,
thus possibly promoting the development of osteo-
porosis.15—18 Peak bone mass may not be achieved in
adolescent girls. Other worrisome side effects
include a delayed return to fertility19 for many
months, in some cases even more than 1 year.
Women on DMPA may also complain about weight
gain, skin problems like acne or hair loss, and
depressive symptoms. Thus the decision whether
to use depot preparations in women on EI-AEDs
should take into account all the risks and benefits
of this contraceptive choice for the individual
patient.Are IUDs or the levonorgestrel-IUS an
alternative for women with epilepsy?
The classic intrauterine copper or silver device (IUD)
or the newer levonorgestrel releasing intrauterine
system (IUS) (Mirena1) as it is called by the manu-
facturing company may be an alternative for women
with epilepsy an EI-AEDs. The IUS has steroid reser-
voir that releases 20 mg of levonorgestrel in the
uterine cavity. Over time the release rate decreases
slowly to 15 mg/day. The device is approved for 5
years. Most of the contraceptive effect is mediated
via local mechanisms: the high tissue concentration
of levonorgestrel in the endometrium results in a
suppression of endometrial growth, which in turn
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amount of menstrual bleeding. Many women experi-
ence amenorrhoea, which should not be judged as
an unwanted side effect but an external sign that
system is in proper position. Other contraceptive
mechanisms include cervical mucus hostility which
gives additional protection against the progression
of sexual transmitted infections to pelvic inflamma-
tory disease (PID) with possible later fertility pro-
blems.20 Since the IUS exerts its contraceptive
properties mainly by local uterine mechanisms it
is on theorethical grounds very unlikely that EI-AEDs
impair its contraceptive efficacy. This is supported
by an observational series on women using the IUS
Mirena1 concurrently with antiepileptic and other
enzyme-inducing drugs. The authors of the study
concluded, that if there is any increased pregnancy
risk, it falls within ‘‘acceptable bounds’’.21 In con-
trast to usual COCs the levonorgestrel-IUS does not
seem to influence lamotrigine plasma levels (own
observation in six patiens).
Thus the IUS (and to a lesser extent the IUDs) are
a good alternative to the classical hormonal contra-
ceptives in women with epilepsy, especially if they
are taking enzyme inducers or lamotrigine. Yet
many health care providers are reluctant to recom-
mend IUDs or the IUS due to myths and misconcep-
tions, e.g. the belief that IUDs cause PID or
infertility and should consequently not be used in
younger womenwho have not given birth. However,
studies indicate that there is only a small increased
short-term risk of PID in IUD users during the 1st
weeks after insertion. After this time, PID risk
appears comparable to that of women not using
an IUD. Furthermore studies show that the biggest
risk factor for PID and resulting tubal sterility in
young women using IUDs is their and their partner’s
sexual behaviour (i.e. promiscuity). Newer clinical
trials suggest that there is little or no good evidence
that the prior use of a copper-containing IUD
increases the risk for impaired fertility.22—24 Keep-
ing in mind the IUSs pronounced effect on the
cervical mucus, which is likely to prevent the
ascend and progression of vaginal and cervical
infections to endometritis and PID, health care
suppliers should no longer withhold the IUS because
of their fear to promote infertility.Emergency contraception
High doses of progestin after intercourse can pre-
vent pregnancy in a majority of women without
contraception. There are no data on what doses
are needed in women on EI-AEDs, but current guide-
lines recommend a higher dose (1.5 mg levonorges-trel instead of 0.75 mg as soon as possible followed
by 0.75 mg 12 h later).Conclusion
A neurologist should never forget to ask a women, if
and what type of contraception she is using before
prescribing an AED. The decision, which AED to use,
or which contraceptive method is optimal for an
individual womanwith epilepsy depends on a variety
of factors. The bidirectional interactive potential of
AEDs and hormonal contraceptives needs to be
taken into account when counselling women with
epilepsy. Alternatives such as the use of an IUD or IUS
should be kept in mind if standard hormonal contra-
ceptives to not appear to offer the contraceptive
safety, that is wanted in an individual patient or if
potential side effects of the contraceptive method
do not warrant their use.References
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